A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma.
Ri M et al. Intern Med. 2017 Dec 8. doi: 10.2169/internalmedicine.9567-17. [Epub ahead of print].
Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.
Meyers DE et al. Blood Cancer J. 2017 Dec 5;7(12):640. doi: 10.1038/s41408-017-0020-0.
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom’s macroglobulinemia.
Chen C et al. Blood. 2017 Dec 4. pii: blood-2017-08-797886. doi: 10.1182/blood-2017-08-797886. [Epub ahead of print].
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Salvini M et al. Expert Opin Drug Metab Toxicol. 2017 Dec 13. doi: 10.1080/17425255.2018.1417388. [Epub ahead of print].